RT Journal Article SR Electronic T1 Development of the interstitial lung disease multidiciplinary team meeting 2005-2013 JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP PA333 DO 10.1183/13993003.congress-2015.PA333 VO 46 IS suppl 59 A1 Geraldine Burge A1 Salman Ghani A1 Dimitrina Petkova A1 John Reynolds A1 Madava Djearman A1 Shahid Hussain A1 Ed Hoey A1 Simon Trotter A1 Gerald Langman A1 Abdul Faizal A1 Sherwood Burge YR 2015 UL http://erj.ersjournals.com/content/46/suppl_59/PA333.abstract AB Introduction: NICE made recommendations for MDT management of IPF in 2013 against which we have audited our results.Methods: Following presentation of the history, examination, physiology, immunology and any biopsies, the MDT decides whether there is sufficient evidence to make a confident diagnosis; if not it recommends further investigations that should lead to a definitive diagnosis. If the disease is too advanced for safe further investigations the MDT makes a most likely diagnosis.Results: Patients discussed have risen from 81 in 2005 to 203 in 2013. The commonest diagnoses in 2013 were IPF (60), NSIP alone (19), Sarcoidosis (25), HP (17), ILD with CVD (12) and Asbestosis (9). The proportion where VATS was recommended or carried out for UIP has reduced from 41% in 2007 to 22% in 2013. Histological confirmation of sarcoidsis was low (12/25). Only 15 of the 51 patients with definite IPF had FVC <80% required for Pirfenidone prescription in the UK. Fig 1 shows the relationship between VC and DLCO % pedicted for IPF patients at presentation.Conclusions: The prescription criteria for Pirfenidone in the UK exclude most patients with IPF. Compared with guidelines the biopsy rate for probable sarcoidosis is low (48%). The workup of patients with possible chronic HP/NSIP is often hampered by the lack of occupational, environmental, drug and immunological data.